Adma Biologics reported $431.19M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Adma Biologics USD 431.19M 32.87M Sep/2025
Alnylam Pharmaceuticals USD 789.18M 555.28M Dec/2025
BioCryst Pharmaceuticals USD -387.89M 33.7M Sep/2025
Minerva Neurosciences USD -34.58M 2.47M Sep/2025
Novavax USD -156.67M 194.3M Sep/2025
Omeros USD -228.68M 15.13M Jun/2025
Takeda JPY 7.64T 513.39B Dec/2025